Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
Ian A. MacNeil(Acuity Technologies (United States)), Lance Laing(Acuity Technologies (United States))
Cited by 2
Related Papers
Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy
|International Journal of Molecular Sciences|2025|0